TETmedical Appointed New Chief Commercial Officer
The diagnostics firm has hired Arjun Ishwar to build its commercial infrastructure for a future product launch.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Do you trust emerging medical diagnostics companies to deliver life-saving technology to hospitals efficiently?
TETmedical has named industry veteran Arjun Ishwar as its new Chief Commercial Officer. Ishwar will lead the effort to scale the company's commercial operations as it works toward a pivotal study and market release for its NSE-FAST diagnostic tool.
Why it matters
The hire marks a strategic step for TETmedical as it seeks to bridge the gap between recent regulatory achievements and a successful U.S. product launch. By strengthening its executive leadership, the company aims to move NSE-FAST from a Breakthrough Device status to broad commercial availability.
Ishwar brings 15 years of diagnostic experience to the firm, having previously driven 4x revenue growth at MY01 and managed $100 million in annual revenue during his time at ACell.
The players
Arjun Ishwar
He is the newly appointed Chief Commercial Officer at TETmedical with 15 years of experience in the diagnostics industry.
TETmedical
This diagnostic company operates out of Fair Haven, N.J., and Ithaca, N.Y., and is currently developing the NSE-FAST device.
The details
Ishwar joins the Fair Haven and Ithaca-based company to establish the commercial infrastructure required for the NSE-FAST diagnostic device. His background includes commercial leadership roles at Miach Orthopedics, where he managed a team of 45 direct sales members and 20 indirect agency partners.
Timeline
Integra LifeSciences acquired ACell, Inc. in 2021.
Arjun Ishwar led commercial growth for Miach Orthopedics from 2022 to mid-2026.
The FDA granted NSE-FAST Breakthrough Device Designation on June 15, 2026.
TETmedical announced the appointment of Arjun Ishwar on September 29, 2026.
TETmedical plans to initiate a multi-center pivotal study in Q4 2026.
Market Landscape
The appointment follows the timeline set by the FDA Breakthrough Device Designation program, which is designed to expedite the review of novel medical technologies like NSE-FAST. This hire suggests TETmedical is shifting from early-stage R&D toward a competitive go-to-market strategy in the diagnostics sector.
The appointment signals that the company is preparing to ramp up its U.S. presence, which may impact which diagnostic products are available to medical providers in the near future. Healthcare consumers and providers should monitor the upcoming Q4 study for updates on product accessibility and clinical adoption.
The takeaway
Effective commercial leadership is essential for diagnostic startups transitioning from regulatory approval to large-scale market adoption. The company's ability to mirror Ishwar's past success in scaling sales teams will determine the commercial viability of its new diagnostic platform.
What happens next
TETmedical is scheduled to initiate a multi-center pivotal study for its NSE-FAST device in the fourth quarter of 2026.
Further reading
For more on industry shifts, visit the Healthcare section.
More information
For more details on the company's progress, visit the TETmedical company information portal.
Live Poll
Do you trust emerging medical diagnostics companies to deliver life-saving technology to hospitals efficiently?
